Clinical Trials Logo

Premenstrual Dysphoric Disorder clinical trials

View clinical trials related to Premenstrual Dysphoric Disorder.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06227676 Completed - Clinical trials for Polycystic Ovary Syndrome

Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25

NUTRITION; GYN
Start date: July 21, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

85 percent of women of reproductive age experience consistent period cramps/menstrual pain, and 60% indicate that they do not use painkillers to relieve menstrual symptoms; there is a need for natural and non-medicative supplements to dysmenorrhea. The purpose of this clinical trial is to examine the effect of 'Cramp Bites'--classified by a mixture of natural ingredients researched to help with period pain--on women suffering from primary dysmenorrhea: this will be done through providing participants with the snack and surveying them on how it changes their period symptoms.

NCT ID: NCT06136104 Completed - Healthy Clinical Trials

The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

Start date: August 30, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess Mixhers HERTIME supplements efficacy in alleviating menstrual cycle symptoms.

NCT ID: NCT03862469 Completed - Clinical trials for Premenstrual Dysphoric Disorder

Premenstrual Hormonal and Affective State Evaluation (PHASE) Project

PHASE Project
Start date: September 26, 2019
Phase: N/A
Study type: Interventional

PHASE is designed to evaluate neuroactive hormone trajectories across the menstrual cycle and endocrine, autonomic, and subjective responses to psychosocial stress in women suffering from severe PMS (i.e., premenstrual dysphoric disorder).

NCT ID: NCT03697265 Completed - Clinical trials for Premenstrual Dysphoric Disorder

A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)

Start date: April 20, 2018
Phase: Phase 2
Study type: Interventional

The objective of this phase IIb study is to evaluate the effect and safety of Sepranolone (UC1010) on premenstrual symptoms in women with Premenstrual Dysphoric Disorder (PMDD). Patients will be taking Sepranolone or Placebo (blinded to patient and study doctor) during the two weeks preceding the menstruation of three menstrual cycles. Effect (change from baseline) will be assessed by comparison of symptoms recorded daily by the patients using a validated rating scale for assessment of PMDD symptoms. Sepranolone is an endogenous steroid.

NCT ID: NCT03449979 Completed - Depression Clinical Trials

Single Session of tACS in a Depressive Episode

SSDE
Start date: September 19, 2018
Phase: N/A
Study type: Interventional

Purpose: Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on healthy participants and participants with mood disorders. Participants: 40 males and females, ages 18-65, with depressed mood; 40 healthy males and females, ages 18-65, free of neurological or psychiatric conditions. Procedures: This is a single visit study with two stimulation conditions (tACS and sham tACS). The session will begin with clinical assessments (including confirmation of diagnosis), followed by an interactive EEG task, then a 7 minute resting state EEG (2 minutes eyes closed, 5 minutes eyes open), followed by the stimulation session (40 minutes of tACS or sham tACS), followed by an additional 5 minute resting state EEG. The stimulation will involved 40 minutes of transcranial alternating current stimulation, 2 mA in amplitude and at individualized alpha frequency (determined by the 2 minutes eyes closed EEG recording; between 8 and 12Hz).

NCT ID: NCT01875718 Completed - Clinical trials for Premenstrual Dysphoric Disorder

A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)

Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a phase 1/2 study in two parts. In part 1, the primary objective is to assess the pharmacokinetics of UC1010 when administered subcutaneously as a single dose to healthy women. The safety and tolerability of UC1010 is also evaluated in study part 1. In part 2, the primary objective is to assess the pharmacodynamic effect of UC1010 on premenstrual symptoms in women with Premenstrual Dysphoric Disorder (PMDD) when given during the luteal phase of the menstrual cycle. The pharmacodynamic effect is evaluated through the patients' daily ratings of premenstrual symptoms. In both study parts, two active treatment groups are compared to one placebo group.

NCT ID: NCT01799733 Completed - Clinical trials for Premenstrual Dysphoric Disorder

Alternative Treatments for Premenstrual Dysphoric Disorder

Start date: June 18, 2013
Phase: N/A
Study type: Interventional

The primary aim of this study is to examine the effects of co-administered wake therapy followed by light treatment on mood, and secondarily on circadian rhythms, to test the hypothesis that critically-timed chronotherapy improves mood by correcting phase disturbances in melatonin and sleep in women with Premenstrual Dysphoric Disorder.

NCT ID: NCT01385709 Completed - Clinical trials for Major Depressive Disorder

The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels

Start date: August 2008
Phase: N/A
Study type: Observational

The aim of this study is to determine whether blood levels of lithium or sertraline are affected by different phases of the menstrual cycle and whether there is an effect on psychiatric symptoms. Subjects are seen for two visits: one visit during the luteal phase and one visit during the follicular phase of the menstrual cycle. On each visit, they will fill out a depression, anxiety and mania rating scale. Also at each visit a 20mL blood sample will be drawn to measure progesterone level and either a lithium or sertraline level, depending on which medication the patient takes. The primary hypothesis in this study is that blood levels of lithium and sertraline will be significantly lower in women during the luteal phase of the menstrual cycle than during the follicular phase. Examination will also be made of whether symptoms will increase in severity during the luteal phase as compared to the follicular phase. The investigators expect a negative linear association between symptom severity and blood level, i.e. expect symptom severity to worsen as blood levels of lithium or sertraline decrease.

NCT ID: NCT00927095 Completed - Clinical trials for Premenstrual Dysphoric Disorder

Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)

PMDD
Start date: July 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare a low dose oral contraceptive (OC) given continuously (every day for three months) with the same low dose oral contraceptive given in an interrupted regimen (one week of inactive placebo pills each month) and with continuous placebo (inactive placebo given every day for three months). The primary hypothesis is that continuous OC will be significantly more effective in reducing premenstrual symptoms compared with either the interrupted OC or continuous placebo.

NCT ID: NCT00678574 Completed - Clinical trials for Premenstrual Syndrome

The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder

Start date: March 1998
Phase: Phase 4
Study type: Interventional

The purpose of the study proposed is to investigate the role of neurosteroids and GABA in the pathophysiology and treatment of premenstrual dysphoric disorder (PMDD) by 1) measuring cortical gama-aminobutyric acid levels (GABA levels) using nuclear magnetic resonance spectroscopy (MRS) during the follicular and mid-luteal phases of the menstrual cycle pre and post treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®, Sarafem®), and 2) correlating cerebrospinal fluid (CSF) and plasma GABA and neurosteroid levels with cortical GABA levels at these same time points. Neurosteroids to be measured include allopregnanolone, pregnenolone, and pregnenolone sulfate. Findings from women with PMDD will be compared to those of healthy subjects.